Microbot Medical's Cash Burn Concerns Despite Long Runway

Microbot Medical (NASDAQ:MBOT) is an unprofitable company, but that doesn't necessarily mean investors should worry. While unprofitable businesses can be risky, some, like Salesforce.com, have managed to generate significant returns for shareholders over time. The key concern for Microbot Medical is its cash burn rate, how quickly it spends cash to fund its growth.

As of June 2026, Microbot Medical had no debt and US$67 million in cash. With a cash burn rate of US$18 million over the last year, the company has a cash runway of about 3.8 years. This is a reassuringly long runway, but the company's cash burn increased by a significant 81% over the past year. While this spending is likely aimed at driving growth, if the trend continues, the company's cash runway could shrink rapidly.

Microbot Medical has a market capitalization of US$78 million, and its cash burn of US$18 million represents 23% of its market value. This level of cash burn is notable, and if the company needs to raise more cash, shareholders could face dilution. Despite these concerns, the company's cash runway is currently stable, and investors may not need to be overly worried, though they should keep an eye on its cash burn trends.